S0025 Irinotecan in Treating Patients With Refractory Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00053833 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

NETWORK

Sponsor class

Stopped lack of accrual

Conditions

Fallopian Tube Cancer
Ovarian Cancer
Primary Peritoneal Cavity Cancer

Interventions

DRUG: irinotecan

Sponsor

SWOG Cancer Research Network

Collaborators

[object Object]